(ALXO) Alx Oncology Holdings - Ratings and Ratios

Alx Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on developing innovative cancer therapies. Their lead candidate, Evorpacept, is a CD47-blocking therapeutic biologic designed to enhance anti-cancer immune responses when combined with other agents. CD47 is a protein overexpressed on cancer cells that can evade immune detection, making it a strategic target. Evorpacepts mechanism involves inhibiting this evasion, potentially improving the effectiveness of combination therapies.

Evorpacept is being evaluated in multiple clinical trials. The ASPEN-06 study is a Phase 2 trial investigating Evorpacept combined with other agents for gastric/GEJ cancer. ASPEN-07 is a Phase 1 trial targeting urothelial cancer, while ASPEN-03 and ASPEN-04 are Phase 2 studies for head and neck squamous cell carcinoma. These trials highlight the versatility of Evorpacept across various cancer types, addressing significant unmet needs in oncology.

Strategic collaborations enhance Alx Oncologys development pipeline. Partnerships with Jazz Pharmaceuticals, Quantum Leap Healthcare, MD Anderson, and others aim to explore Evorpacept in combination with zanidatamab, ADCs, and other agents, targeting cancers such as breast, multiple myeloma, and colorectal cancer. Additionally, collaborations with academic institutions like the University of Pittsburgh expand Evorpacepts potential in ovarian cancer. These alliances underscore a commitment to comprehensive combination strategies in oncology.

Looking ahead, the 3-month forecast for ALXO stock suggests cautious bearish sentiment. Technically, the stock trades below its 20, 50, and 200-day moving averages (1.09, 1.42, 3.42 respectively), indicating a downtrend. The Average True Range (ATR) of 0.13 signals low volatility, suggesting price stability but within a constrained range. Fundamentally, while the high P/S ratio may indicate revenue potential, the lack of profitability (P/E: 0.00) and micro-cap status (Market Cap: $52.74M) pose risks. Investors should monitor clinical trial progress and partnership developments for potential catalysts, though the stock may remain range-bound or decline further in the near term.